Table 5.

Effect of aspirin formulation and dose on risk of UGIB and perforation among current users as compared to non-use

	All cases	Controls	Adjusted RR*
	(N=2,105)	(N=11,500)	(95%CI)
Formulation/dose as instructed
Plain
≤ 150 mg	201	626	1.9 (1.6-2.2)
300 + mg	30	69	2.6 (1.6-4.2)
Enteric-coated
≤ 150 mg	24	39	3.5 (2.0-6.1)
300 + mg	32	103	1.8 (1.2-2.8)

^* Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment for antiulcer drugs use did not change the estimates.